Free Trial
→ Did you grab your copy yet? (From Profits Run) (Ad)tc pixel
NASDAQ:RVMDW

Revolution Medicines Earnings Date & Estimates

Revolution Medicines logo
$10.02 +0.57 (+6.03%)
As of 04:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Revolution Medicines is estimated to report earnings on Wednesday, November 11, 2026, after market closes.

Research:Profile

Upcoming Earnings Announcement

Announcement Date
Time
After Market Closes
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Revolution Medicines

Revolution Medicines is expected to post earnings of -$2.3474 per share on revenue of $23.74 million.

Consensus Estimates

Consensus EPS
-$2.3474
Expected Revenue
$23.74 million

Prepare for the Earnings Call

Revolution Medicines Earnings FAQ

Revolution Medicines (NASDAQ:RVMDW) is estimated to report earnings on Wednesday, November 11, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Analysts expect Revolution Medicines to post earnings of -$2.3474 per share for the quarter.

The consensus revenue estimate for Revolution Medicines is $23.74 million for the quarter.

Revolution Medicines Earnings Headlines

Revolution Medicines Inc (RVMD)
October 11 at 3:15 PM  |  in.investing.comhttps://in.investing.com/equities/revolution-medicines-inc-news
First-Line RAS G12D Pancreatic Cancer Trial Launch Could Be A Game Changer For Revolution Medicines (RVMD)
October 7, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/first-line-ras-g12d-pancreatic-042740218.html
Urgent: Invest In ‘Elon’s iPhone’ Before July 22nd
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider sources say Elon Musk is developing a breakthrough technology he describes as '10x bigger than the largest product in history.' Nvidia's CEO has called it 'the next biggest opportunity after AI,' with potential lifetime sales reaching $20 trillion.tc pixel
October 14 at 1:00 AM  |  StocksToTrade (Ad)
Biotech stocks tumble, with recent winners Moderna, Vaxcyte among the biggest losers
October 6, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/biotech-stocks-tumble-with-recent-winners-moderna-vaxcyte-among-the-biggest-losers/ar-AA2dGsnE
Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS ...
October 5, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/revolution-medicines-begins-treating-patients-in-phase-3-rasolute-309-trial-evaluating-rasonque-daraxonrasib-plus-zoldonrasib-as-first-line-treatment-for-metastatic-ras-g12d-pancreatic-cancer-1036596803
Revolution Medicines Seen Having 'Strong' Rasonque Launch in Pancreatic Cancer, UBS Says
September 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/revolution-medicines-seen-having-apos-155816013.html
See More Revolution Medicines Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Revolution Medicines? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Revolution Medicines and other key companies, straight to your email.

About Revolution Medicines

Revolution Medicines (NASDAQ:RVMDW) is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer. The company specializes in medicines designed to inhibit mutated RAS proteins, including KRAS, which are important drivers of many solid tumors and have historically been difficult to target with drugs.

Its research and development pipeline includes RAS(ON) inhibitors intended to block active forms of RAS signaling. Key investigational programs have included pan-RAS inhibitors and mutation-selective candidates directed at alterations such as KRAS G12C and KRAS G12D. These programs are being evaluated for potential use across multiple cancers, including colorectal, pancreatic and lung cancers.

Founded in 2014 and headquartered in Redwood City, California, Revolution Medicines conducts its research and clinical development activities primarily in the United States while pursuing therapies intended for patients globally. The company is led by President and Chief Executive Officer Robert M. Morgan, Ph.D., and its securities trade on Nasdaq under several symbols, including RVMDW for a warrant security.

View Revolution Medicines Profile
Earnings Tools